Medical Treatment of Hepatocellular Carcinoma
Author Information
Author(s): Alessandro Granito, Luigi Bolondi
Primary Institution: Policlinico S. Orsola Malpighi, Bologna, Italy
Conclusion
New therapies, including sorafenib, have shown survival benefits for patients with advanced hepatocellular carcinoma.
Supporting Evidence
- Hepatocellular carcinoma is the fifth most common cancer and a leading cause of cancer-related deaths.
- Surveillance programs for high-risk populations can improve early detection and treatment outcomes.
- Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma.
Takeaway
Hepatocellular carcinoma is a serious liver cancer, but there are treatments that can help people live longer, especially if caught early.
Methodology
The article reviews various treatment options for hepatocellular carcinoma, including surgical and non-surgical methods.
Limitations
The study does not provide definitive data on all treatment options and their effectiveness across different patient demographics.
Participant Demographics
The article discusses various demographics affected by hepatocellular carcinoma, including those with chronic hepatitis B and C.
Statistical Information
P-Value
p=0.005
Confidence Interval
95% CI 0.55–0.87
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website